An immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres, and its preparation method and application

By preparing antibody-labeled AIE magnetically encoded microspheres and nano-microspheres, combined with double-wavelength aggregation-induced luminescent magnetically encoded microspheres and active swelling method, the problem of fluorescence quenching of traditional materials is solved, and efficient and stable multi-item immune detection is achieved .

CN118068010BActive Publication Date: 2024-11-05AIE INSTITUTE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410144983.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-01
Publication Date
2024-11-05
Estimated Expiration
2044-02-01

AI Technical Summary

Technical Problem

The lack of efficient preparation of AIE magnetic fluorescence encoded microspheres in the prior art limits the application of high-throughput biochips. Traditional organic materials experience fluorescence quenching in aggregation state, limiting the encoding capacity and stability.

Method used

Using the immunodetection reagent of AIE magnetically encoded microspheres and AIE nano-microspheres, the combination of antibody-labeled AIE magnetically encoded microspheres and antibody-labeled AIE nano-microspheres is used to induce luminescence magnetically encoded microspheres and active swelling method. AIE molecules were buried and magnetic particles were deposited in combination with in situ precipitation to prepare efficient AIE magnetically encoded microspheres.

Benefits of technology

It achieves a high-distinguishing fluorescence signal, avoids the fluorescence reabsorption effect, improves light stability, and can maintain the intensity of the fluorescence signal under repeated irradiation. It is suitable for multi-item quantitative immunoassays.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118068010B_ABST
    Figure CN118068010B_ABST
Patent Text Reader

Abstract

The present invention discloses an immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres, and a preparation method and application thereof; the immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres comprises AIE magnetically encoded microspheres labeled with antibody-1 and AIE nanospheres labeled with antibody-2. The present invention adds AIE magnetically encoded microspheres labeled with antibody-1 and AIE nanospheres labeled with antibody-2 to a test solution containing corresponding antigens, and after the reaction, passes through a flow cytometer, and is separated by magnetic absorption to obtain encoding peaks and fluorescence quantitative detection concentrations. The present invention utilizes the high zone of AIE magnetically encoded microspheres and the signal amplification effect of quantitative detection of AIE magnetically encoded microspheres to achieve long linear range detection in complex samples of multiple markers; and provides a new detection strategy for multiple marker immunoassay.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of in vitro diagnosis, and in particular relates to an immunoassay reagent based on AIE magnetically encoded microspheres and AIE nano-microspheres, and a preparation method and application thereof. Background Art

[0002] The development and completion of the human genome and proteome in recent years has led to a huge demand for large-scale analysis of biomolecules, which has promoted the rapid development of liquid suspension biochips with encoded microspheres as the core. Liquid suspension biochips with rapid high-throughput flow cytometry and magnetic separation as analytical methods have gradually become a new goal for accurate diagnosis by performing rapid and high-throughput multiplex detection of markers such as proteins, nucleic acids and small molecules. Among them, the development of encoded microspheres with high encoding capacity and stability is still a huge challenge. The design of suitable encoded microspheres has the following requirements: high photostability, good anti-magnetism, large number of codes, no reabsorption and crosstalk effects, etc.

[0003] Spectral signals are widely used in the construction of liquid biochips due to their flexible encoding and fast decoding speed. At present, the commonly used spectral encoding materials are mainly organic materials, quantum dots, upconversion dots and photonic crystals, etc. Quantum dots have become popular encoding materials due to their high brightness and narrow emission spectrum, but the encoding ability of quantum dots is limited by the reabsorption and cross-color effect between quantum dot fluorescence signals, which limits the application of quantum dot encoding microspheres.

[0004] At present, commercial liquid biochip Luminex system and BD's cytometric bead array all use organic dyes for encoding, but traditional organic materials have fluorescence quenching in the aggregated state, which limits the encoding capacity and stability of traditional organic materials. The new aggregation-induced emission (AIE) material discovered by the team of Academician Tang Benzhong in 2001 is a promising encoding material for the preparation of encoded microspheres, because AIE materials can achieve in-situ enhancement of fluorescence signals during the aggregation process. Aggregation-induced emission materials have properties such as large Stokes shift, strong resistance to photobleaching, and anti-magnetism, and are an excellent material for encoding microspheres.

[0005] Until recently, Li Wanwan used membrane emulsification technology to prepare AIE non-magnetic encoded microspheres for the detection of multiple markers. However, the lack of magnetic materials made it impossible to achieve the goal of high-throughput testing. Nowadays, there are few public reports on the efficient preparation of AIE magnetic fluorescent encoding using AIE materials. Therefore, it is necessary to develop a technology for the efficient and direct generation of AIE magnetic encoded microspheres. Summary of the invention

[0006] In order to solve the deficiencies in the prior art, the present invention aims to provide an immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres, and a preparation method and application thereof.

[0007] The technical solution adopted by the present invention is:

[0008] An immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres comprises AIE magnetically encoded microspheres labeled with antibody-1 and AIE nanospheres labeled with antibody-2.

[0009] Preferably, the mass amount of the AIE nanospheres labeled with antibody-2 is 0.001-0.01wt% of the mass amount of the AIE magnetically encoded microspheres labeled with antibody-1;

[0010] Preferably, the particle size ratio of the AIE magnetically encoded microspheres to the AIE nanospheres is (10-350):1;

[0011] Further preferably, the particle size ratio of the AIE magnetically encoded microspheres to the AIE nanospheres is (100-350):1;

[0012] Further preferably, the particle size range of the AIE magnetically encoded microspheres is 1.5 μm-20 μm; the particle size range of the AIE nanospheres is 10 nm-1000 nm;

[0013] Preferably, the antibody-1 and antibody-2 can specifically bind to the same antigen.

[0014] Further preferably, the antigen is a cytokine marker, including IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α, and IFN-γ.

[0015] Further preferably, the antibody-1 is selected from at least one of IL-2 monoclonal antibody, IL-4 monoclonal antibody, IL-6 monoclonal antibody, IL-10 monoclonal antibody, IL-17 monoclonal antibody, TNF-α monoclonal antibody and IFN-γ monoclonal antibody; antibody-2 is selected from the anti-antibody of antibody-1;

[0016] Further preferably, the antibody-1 and antibody-2 are mouse antibodies.

[0017] Preferably, the emission wavelength of the AIE nanospheres is in the range of 450nm-550nm;

[0018] Preferably, the AIE nanospheres include carboxyl-modified blank polymer nanospheres and AIE-N molecules; the AIE-N molecules are embedded in the carboxyl-modified blank polymer nanospheres;

[0019] Further preferably, in the AIE nanospheres,

[0020] The carboxyl-modified blank polymer nanospheres are selected from at least one of carboxyl-modified polystyrene microspheres, carboxyl-modified polymethyl methacrylate microspheres and carboxyl-modified polyglycidyl acrylate microspheres;

[0021] The AIE-N molecules are embedded in the blank polymer nanospheres modified with carboxyl groups by an active swelling method, wherein the amount of the AIE-N molecules used in the active swelling method is 0.01-10 wt % of the amount of the blank polymer nanospheres modified with carboxyl groups.

[0022] The AIE-N molecules in the AIE nanospheres are selected from at least one of the following AIE-N1 to AIE-N10:

[0023]

[0024]

[0025] The alkyl chains in AIE-N8, AIE-N9 and AIE-N10 molecules -C8H 17 Each is independently a branched chain alkyl or a straight chain alkyl.

[0026] More preferably, the active swelling method is to allow the AIE-N molecules to swell with the carboxyl-modified blank polymer nanospheres in a swelling agent so that the AIE-N molecules are embedded in the carboxyl-modified blank polymer nanospheres;

[0027] In the active swelling method, the swelling agent is selected from at least one of dichloromethane, tetrahydrofuran, chloroform, anisole, benzyl alcohol and toluene, and the particle size of the carboxyl-modified blank polymer nanospheres ranges from 10nm to 500nm; the carboxyl-modified blank polymer nanospheres are nanoscale microsphere matrices known in the art.

[0028] Preferably, the preparation method of the AIE nanospheres comprises the following steps:

[0029] (1) dispersing carboxyl-modified blank polymer nanospheres in water to obtain a nanosphere dispersion;

[0030] (2) dissolving the AIE-N molecules in a swelling agent to obtain an AIE swelling agent solution;

[0031] (3) adding the AIE swelling agent solution described in step (2) to the microsphere dispersion described in step (1), and after ultrasonic treatment, closing the reactor to carry out swelling reaction. After the reaction is completed, volatilizing and removing the swelling agent to obtain AIE nanospheres;

[0032] Further preferably, the method for preparing the AIE nanospheres comprises the following steps:

[0033] (1) dispersing carboxyl-modified blank polymer nanospheres in water to obtain a nanosphere dispersion;

[0034] (2) dissolving the AIE-N molecules in a swelling agent to obtain an AIE swelling agent solution;

[0035] (3) adding the AIE swelling agent solution described in step (2) to the microsphere dispersion described in step (1), and subjecting the mixture to ultrasonic treatment for 1 min to 30 min at an ultrasonic power of 50 W to 400 W, and conducting a swelling reaction in a closed reactor for 0.5 h to 4 h. After the reaction is completed, the swelling agent is volatilized to obtain AIE nanospheres;

[0036] Further preferably, in step (1), the mass amount of the carboxyl-modified blank polymer nano-microspheres in the microsphere dispersion is 0.1% to 20% of the mass amount of water;

[0037] Further preferably, in step (2), the mass amount of AIE-N molecules in the AIE swelling agent solution is 0.05% to 20% of the mass amount of the swelling agent; further preferably, the mass amount of AIE-N molecules in the AIE swelling agent solution is 0.1% to 5% of the mass amount of the swelling agent.

[0038] Further preferably, in step (3), the time for volatilizing and removing the swelling agent is 2 hours to 10 hours.

[0039] Preferably, the encoding capacity of the AIE magnetically encoded microspheres is ≥ 9, and the CV value of the flow fluorescence signal and the CV value of the flow FCS are both less than 10%;

[0040] Preferably, the encoding capacity of the AIE magnetically encoded microspheres is ≥24; the AIE magnetically encoded microspheres are dual-wavelength aggregation-induced luminescence magnetically encoded microspheres, including AIE polymer microspheres and magnetic particles; the AIE polymer microspheres are obtained by embedding AIE molecules inside blank polymer microspheres, and the magnetic particles are deposited on the surface of the AIE polymer microspheres; the AIE molecules include AIE-R molecules and AIE-IR molecules;

[0041] The difference between the maximum emission wavelength of the AIE-IR molecule and the maximum emission wavelength of the AIE-R molecule is in the range of 160 nm to 290 nm, and satisfies Δλ≥185. Where I / I0 is the average value of the fluorescence intensity ratio of AIE-IR molecules and AIE-IR molecules before and after embedding, λ IR is the maximum emission wavelength of the AIE-IR molecule, λ R is the maximum emission wavelength of the AIE-R molecule.

[0042] More preferably,

[0043] In the dual-wavelength aggregation-induced luminescence magnetically encoded microspheres,

[0044] The blank polymer microspheres are selected from at least one of polystyrene microspheres, polymethyl methacrylate microspheres and polyglycidyl acrylate microspheres; more preferably, the blank polymer microspheres are selected from polystyrene microspheres or polyglycidyl acrylate microspheres.

[0045] The magnetic particles are Fe3O4;

[0046] The AIE-R molecule is selected from at least one of the following AIE-R1 to AIE-R16 molecules:

[0047]

[0048]

[0049]

[0050] Alkyl chain in AIE-R1 molecule - C8H 17 Each is independently a branched chain alkyl or a straight chain alkyl.

[0051] Alkyl chain in AIE-R11 molecule - C6H 13 Each is independently a branched chain alkyl or a straight chain alkyl.

[0052] The AIE-IR molecule is selected from at least one of the following AIE-IR1 to AIE-IR10 molecules:

[0053]

[0054]

[0055] The AIE molecules are embedded in the blank polymer microspheres by an active swelling method, wherein the amount of the AIE molecules used in the active swelling method is 0.01-10wt% of the amount of the blank polymer microspheres, wherein the mass amount of the AIE-R molecules accounts for 0.01% to 1000% of the mass amount of the AIE-IR molecules;

[0056] The magnetic particles are deposited on the surface of the AIE polymer microspheres by an in-situ precipitation method of iron salts, wherein the amount of iron salts used in the in-situ precipitation method is 0.1-25 wt % of the amount of blank polymer microspheres used.

[0057] More preferably,

[0058] The active swelling method is to allow the AIE molecules to swell with the blank polymer microspheres in a swelling agent so that the AIE molecules are embedded in the blank polymer microspheres.

[0059] In the active swelling method, the swelling agent is selected from at least one of dichloromethane, tetrahydrofuran, chloroform, anisole, benzyl alcohol and toluene, and the particle size of the blank polymer microspheres ranges from 1.5 μm to 20 μm.

[0060] The in-situ precipitation method is to add an alkaline solution to react with the iron salt chelated on the surface of the AIE polymer microspheres in situ to generate magnetic particles that are deposited on the surface of the AIE polymer microspheres;

[0061] In the in-situ precipitation method, the surface of the AIE polymer microspheres is modified by sulfonation, the alkaline solution is selected from at least one of sodium hydroxide solution, ammonia water, potassium hydroxide solution and sodium bicarbonate solution; the iron salt is selected from at least one of trivalent iron salt and divalent iron salt; the trivalent iron salt is selected from at least one of ferric chloride hexahydrate and anhydrous ferric chloride; the divalent iron salt is selected from at least one of ferrous chloride tetrahydrate, ferrous chloride dihydrate, ferrous sulfate and ferrous sulfate heptahydrate.

[0062] Considering the uniformity of magnetic particles deposited on the surface of the AIE polymer microspheres, the iron salt is a compound of a trivalent iron salt and a divalent iron salt, wherein the mass amount of the trivalent iron salt is 10% to 60% of the mass amount of the divalent iron salt.

[0063] Further preferably, the preparation method of the dual-wavelength aggregation-induced luminescence magnetically encoded microspheres comprises the following steps:

[0064] S1. Preparation of AIE polymer microspheres by active swelling method

[0065] (1) dispersing blank polymer microspheres in water to obtain a microsphere dispersion;

[0066] (2) dissolving the AIE molecules in a swelling agent to obtain an AIE swelling agent solution;

[0067] (3) adding the AIE swelling agent solution described in step (2) to the microsphere dispersion described in step (1), and after ultrasonic treatment, closing the reactor to carry out swelling reaction. After the reaction is completed, volatilizing and removing the swelling agent to obtain AIE polymer microspheres;

[0068] S2. Preparation of dual-wavelength aggregation-induced luminescence magnetically encoded microspheres by in situ precipitation

[0069] The AIE polymer microspheres of step S1 are dissolved in a sulfuric acid solution, the temperature is increased for reaction, and the supernatant is removed by centrifugation to obtain AIE polymer microspheres with sulfonation-modified surfaces. The AIE polymer microspheres are mixed with iron salt and water for reaction, and the supernatant is removed by centrifugation to obtain iron salt-chelated AIE polymer microspheres. An alkaline solution is added, and the temperature is increased. The iron salt reacts in situ to generate magnetic particles that are deposited on the surface of the AIE polymer microspheres. The supernatant is removed by centrifugation to prepare dual-wavelength aggregation-induced luminescence magnetically encoded microspheres.

[0070] More preferably, the method for preparing the dual-wavelength aggregation-induced luminescence magnetically encoded microspheres comprises the following steps:

[0071] S1. Preparation of AIE polymer microspheres by active swelling method

[0072] (1) dispersing blank polymer microspheres in water to obtain a microsphere dispersion;

[0073] (2) dissolving the AIE molecules in a swelling agent to obtain an AIE swelling agent solution;

[0074] (3) adding the AIE swelling agent solution described in step (2) to the microsphere dispersion described in step (1), and after ultrasonic treatment at an ultrasonic power of 50 W to 400 W for 1 min to 30 min, a closed reactor is used for swelling reaction for 0.5 h to 4 h. After the reaction is completed, the swelling agent is volatilized to obtain AIE polymer microspheres;

[0075] S2. Preparation of dual-wavelength aggregation-induced luminescence magnetically encoded microspheres by in situ precipitation

[0076] The AIE polymer microspheres of step S1 are dissolved in a sulfuric acid solution, the temperature is increased to 30°C to 100°C and the reaction is carried out for 4h to 12h, and the supernatant is removed by centrifugation to obtain AIE polymer microspheres with sulfonation modified on the surface. The microspheres are mixed with iron salt and water, and the mixture is immersed in the solution for reaction for 0.5h to 10h, and the supernatant is removed by centrifugation to obtain iron salt chelated AIE polymer microspheres. An alkaline solution is added, and the temperature is increased to 60°C to 120°C and the reaction is carried out for 0.5h to 4h. The iron salt reacts in situ to generate magnetic particles which are deposited on the surface of the AIE polymer microspheres. The supernatant is removed by centrifugation to prepare aggregation-induced luminescence magnetically encoded microspheres.

[0077] More preferably, in step S1, the ultrasonic power in step (3) is 300 W, the ultrasonic treatment time is 5 min, and the time for volatilizing and removing the swelling agent is 2 h to 10 h. Further preferably, the time for volatilizing and removing the swelling agent is 4 h.

[0078] More preferably, in step S2, the soaking reaction time is 2 h to 4 h.

[0079] More preferably, in step S1, the mass amount of blank polymer microspheres in the microsphere dispersion is 0.1% to 20% of the mass amount of water; further preferably, the mass amount of blank polymer microspheres in the microsphere dispersion is 0.5% to 10% of the mass amount of water.

[0080] More preferably, in step S1, the mass amount of the AIE molecules in the AIE swelling agent solution is 0.1% to 50% of the mass amount of the swelling agent;

[0081] More preferably, in step S2, the mass concentration of the sulfuric acid solution is 70% to 99%; the mass amount of the AIE polymer microspheres is 1% to 30% of the mass amount of the sulfuric acid solution; further preferably, the mass concentration of the sulfuric acid solution is 98.3%; the mass amount of the AIE polymer microspheres is 5% to 20% of the mass amount of the sulfuric acid solution.

[0082] More preferably, in step S2, the mass dosage of the iron salt is 0.0005% to 25% of the mass dosage of water; the mass dosage of the alkaline solution is 0.1% to 50% of the mass dosage of water; the mass concentration of the alkaline solution is 1% to 10%;

[0083] More preferably, the water in step S1 and step S2 is ultrapure water; the centrifugal speed is 3000 rpm to 6000 rpm, the centrifugal time is 5 min to 60 min, and the number of centrifugation is more than three times.

[0084] The preparation method of the above-mentioned immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres comprises the following steps:

[0085] (1) Carboxyl modification, carboxyl activation, and antibody-1 coupling of the AIE magnetically encoded microspheres to obtain antibody-1 labeled AIE magnetically encoded microspheres;

[0086] (2) activating the carboxyl group of the AIE nanospheres and coupling with antibody-2 to obtain antibody-2 labeled AIE nanospheres;

[0087] The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres is obtained.

[0088] Preferably,

[0089] In step (1), the carboxyl modification comprises: mixing and reacting the AIE magnetic encoded microspheres, a base, TEOS and a silane coupling agent, magnetically separating, and adding a monomer containing a double bond and a carboxyl group to react to obtain the carboxyl modified AIE magnetic encoded microspheres;

[0090] In step (1), the activation of carboxyl groups comprises: dispersing carboxyl-modified AIE magnetic encoded microspheres in an acidic buffer, adding a carbodiimide condensation reagent, and stirring to activate the carboxyl groups, thereby obtaining carboxyl-activated AIE magnetic encoded microspheres;

[0091] In step (1), the antibody-1 coupling comprises: dispersing the AIE magnetically encoded microspheres with activated carboxyl groups in an alkaline buffer, adding the antibody-1, incubating with stirring, separating by magnetic absorption, adding a blocking solution and a preservation solution, and obtaining the AIE magnetically encoded microspheres labeled with the antibody-1;

[0092] In step (2), the activation of carboxyl groups comprises: dispersing the carboxyl-modified AIE nanoparticles in an acidic buffer, adding a carbodiimide condensation reagent, and stirring the reaction to activate the carboxyl groups, thereby obtaining AIE nanoparticles with activated carboxyl groups;

[0093] In step (2), the antibody-2 coupling includes: dispersing the AIE nanoparticles with activated carboxyl groups in an alkaline buffer, adding antibody-2, incubating with stirring, separating by magnetic attraction, adding blocking solution and preservation solution, and obtaining AIE nanoparticles labeled with antibody-2.

[0094] More preferably,

[0095] In the carboxyl modification of step (1), the silane coupling agent is selected from at least one of the following: 3-vinyltrimethoxysilane, methacryloxypropyltrimethoxysilane, vinyltrimethoxysilane, vinyltriethoxysilane;

[0096] In the carboxyl modification of step (1), the monomer containing a double bond and a carboxyl group is selected from at least one of the following: acrylic acid, methacrylic acid, and maleic anhydride;

[0097] In the carboxyl modification of step (1), the base is aqueous ammonia with a concentration of 20% to 28%;

[0098] In the carboxyl modification of step (1), the mass volume ratio of AIE magnetic encoded microspheres, base, TEOS, silane coupling agent and monomer containing double bonds and carboxyl groups is 0.1g:2-3mL:1-1.5mL:0.45-0.6mL:0.3-0.5g; the temperature of the mixed reaction is 25°C-55°C, and the time is 4h-12h; the temperature of adding the monomer containing double bonds and carboxyl groups is 60°C-80°C, and the time is 6h-24h.

[0099] In the activated carboxyl groups in steps (1) and (2), the acidic buffer is glycine-hydrochloric acid buffer, phthalic acid-hydrochloric acid buffer, disodium hydrogen phosphate-citric acid buffer or 2-(N-morpholine)ethanesulfonic acid buffer; the pH value of the acidic buffer is 6.0-6.5;

[0100] In the activated carboxyl group of steps (1) and (2), the carbodiimide condensing agent is selected from at least one of N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride;

[0101] In the steps (1) and (2) of activating the carboxyl group, the activation time of the carboxyl group is 5 min to 3 h;

[0102] In the activated carboxyl group of step (1), the mass amount of the acidic buffer is 10 to 100 times the mass amount of the AIE magnetically encoded microspheres;

[0103] In the activated carboxyl group of step (1), the mass amount of the carbodiimide condensation reagent is 1% to 90% of the mass amount of the AIE magnetically encoded microspheres;

[0104] In the activated carboxyl group of step (2), the mass amount of the acidic buffer is 10 to 100 times the mass amount of the AIE nanospheres;

[0105] In the activated carboxyl group of step (2), the mass amount of the carbodiimide condensation reagent is 1% to 90% of the mass amount of the AIE nanospheres;

[0106] In the antibody-1 coupling of step (1) and the antibody-2 coupling of step (2), the alkaline buffer is tris-hydrochloric acid buffer, boric acid buffer or phosphate buffered saline; the pH value of the alkaline buffer is 7.0 to 9.0;

[0107] In the antibody-1 coupling of step (1), the mass amount of the alkaline buffer is 5 to 90 times the mass amount of the AIE magnetically encoded microspheres.

[0108] In the antibody-2 coupling of step (2), the mass amount of the alkaline buffer is 5 to 90 times the mass amount of the AIE nanospheres.

[0109] In the antibody-1 coupling of step (1), the mass amount of the antibody-1 is 0.005 to 0.02% of the mass amount of the AIE magnetically encoded microspheres.

[0110] In the antibody-1 coupling of step (1), the stirring incubation temperature is 25° C. to 35° C., and the time is 5 min to 3 h.

[0111] In the antibody-2 coupling of step (2), the mass amount of the antibody-1 is 0.005 to 0.02% of the mass amount of the AIE nanospheres.

[0112] In the antibody-2 coupling of step (2), the stirring incubation temperature is 25° C. to 35° C., and the time is 5 min to 3 h.

[0113] The application of the above-mentioned immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres in antigen immunoassay comprises the following steps:

[0114] The AIE magnetically encoded microspheres labeled with antibody-1 and the AIE nanospheres labeled with antibody-2 were added to the test solution containing the corresponding antigens, and after the reaction, they were separated by magnetic absorption, and the encoding peaks and fluorescence quantitative detection concentrations were obtained by flow cytometry.

[0115] Preferably, the corresponding antigen mass dosage is 0.01-1wt% of the mass dosage of the AIE nanoparticles labeled with antibody-2.

[0116] The present invention can use AIE magnetically encoded microspheres labeled with antibody-1 of multiple different antigens and AIE nano-microspheres labeled with antibody-2 of corresponding antigens to detect the solution to be tested respectively, so as to realize the detection of multiple antigens in the solution to be tested; that is, each time the AIE magnetically encoded microspheres labeled with antibody-1 of one antigen and the AIE nano-microspheres labeled with antibody-2 of the corresponding antigen are used to detect the solution to be tested, and this is repeated multiple times.

[0117] The present invention can use AIE magnetic coded microspheres with different coding strengths respectively labeled with antibodies-1 of multiple different antigens and AIE nano-microspheres labeled with antibodies-2 corresponding to antigens to perform one detection on the solution to be tested, thereby realizing the detection of multiple antigens in the solution to be tested; that is, the AIE magnetic coded microspheres labeled with antibodies-1 of multiple different antigens include AIE magnetic coded microspheres with different coding strengths respectively labeled with antibodies-1 of multiple different antigens, and the AIE nano-microspheres labeled with antibodies-2 include AIE nano-microspheres labeled with antibodies-2 corresponding to multiple different antigens; the solution to be tested is detected once.

[0118] The above-mentioned immunoassay reagents based on AIE magnetically encoded microspheres and AIE dyes are used in the field of in vitro non-disease diagnostic testing, such as food testing and public safety testing.

[0119] The present invention marks different types of cytokine antibodies-1 on the surface of AIE magnetically encoded microspheres, and marks corresponding antibodies-2 on the surface of carboxyl-modified AIE nano-microspheres as quantitative detection markers for analysis. Through sandwich immune reaction, the aggregation-induced luminescence property of AIE materials is utilized to realize multi-item quantitative immunodetection of seven cytokine markers (IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α, IFN-γ), and the detection limit concentration ranges from pg·mL -1 ~mg·mL -1 Measure within the range.

[0120] Compared with the prior art, the beneficial effects of the present invention are mainly reflected in:

[0121] (1) Compared with the fluorescent materials of traditional magnetic encoded microspheres, the AIE materials of the aggregation-induced luminescence magnetic encoded microspheres of the present invention improve the discrimination of the magnetic encoded microspheres and solve the fluorescence reabsorption effect of traditional fluorescent materials inside the microspheres. At the same time, the AIE materials have high photostability, so that there is no obvious fluorescence attenuation after repeated irradiation.

[0122] (2) Compared with the traditional ACQ molecules, the water-soluble AIE molecules of the present invention are embedded in the nanospheres, isolating the AIE molecules from the external environment. The signal amplification effect of the AIE nanospheres is utilized during the detection process, and trace detection in low-concentration samples can be achieved even in complex samples with multiple markers.

[0123] (3) The AIE material of the present invention is used as a coding element. Due to the large Stoss shift, there is no reabsorption effect. At the same time, the dipole moment interaction between the two AIE molecules is greater than the FRET process, and the two different AIE molecules have a fluorescence enhancement effect inside the microsphere. At the same time, the AIE material has a typical aggregation-induced emission property. The two different AIE molecules are embedded in the microsphere and can emit strong fluorescence in the aggregate.

[0124] (4) The present invention provides a simple method, which utilizes the high discrimination of AIE encoded microspheres and the signal amplification effect of AIE nanospheres for quantitative detection, to obtain a multi-item immunoassay technology based on AIE magnetic encoded microspheres and AIE nanospheres, providing a new detection strategy for multiple marker immunoassays. BRIEF DESCRIPTION OF THE DRAWINGS

[0125] Figure 1 This is a scanning electron microscope image of the dual-wavelength AIE magnetic encoding microspheres prepared in Example 1.

[0126] Figure 2 Emission spectra of AIE-R1 and AIE-IR1.

[0127] Figure 3 Schematic diagram of flow encoding of dual-wavelength AIE magnetic encoding microspheres prepared in Example 1.

[0128] Figure 4 This is the corresponding coding peak diagram when the seven cytokines are jointly measured in Example 1. DETAILED DESCRIPTION

[0129] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto.

[0130] The blank polymer microspheres in the embodiments and comparative examples are polystyrene polymer microspheres with diameters of 1 μm, 5 μm, 6 μm, 8 μm, and 10 μm, which are from AIE Research Institute and have product numbers of NWKPB-100, NWKPB-500, NWKPB-600, NWKPB-800, and NWKPB-1000.

[0131] The carboxyl-modified blank polymer nanospheres in the examples and comparative examples are carboxyl-modified polystyrene polymer microspheres with diameters of 1000nm, 500nm, 50nm, 40nm, and 30nm, from AIE Research Institute, with product numbers NAGPC-100, NAGPC-050, NAGPC-005, NAGPC-004, and NAGPC-003. Antibody-1, antibody-2, and antigen are from Maichuan (Guangzhou) Biotechnology Co., Ltd., with product number AB10 series.

[0132] Example 1

[0133] 1. Preparation of carboxyl-modified AIE magnetically encoded microspheres

[0134] Weigh 1 g of blank polymer microspheres (particle size 5 μm) and disperse them in 100 g of water to obtain a microsphere dispersion;

[0135] 5 mg of AIE-R1 molecules (alkyl chain -C8H 17 The AIE polymer microspheres were prepared by mixing the two solutions (the total mass of AIE molecules accounted for 1 wt% of the mass of the blank polymer microspheres) and ultrasonically treating them at a power of 100 W for 1 min. After the enclosed swelling for 2 h, the solvent was evaporated for 4 h, and the supernatant was removed by centrifugation to obtain the AIE polymer microspheres. The obtained AIE polymer microspheres were added to 50 mL of concentrated sulfuric acid (98.3 wt%), the temperature was raised to 80 ° C, and the reaction was carried out for 8 h. The microspheres were centrifuged at 5000 rpm and resuspended in water. The reaction was repeated three times to obtain the AIE polymer microspheres with sulfonated surface.

[0136] Ferrous sulfate heptahydrate and ferric chloride hexahydrate were mixed with 100g water in a mass ratio of 2:1 (the total mass of iron salt accounted for 5wt% of the mass of blank polymer microspheres), and the AIE polymer microspheres with sulfonation modified on the surface obtained above were added. After soaking and reacting for 1h, the microspheres were centrifuged at 5000rpm and resuspended in water. The process was repeated three times to obtain iron salt chelated AIE polymer microspheres; 50mL of 1mol / L sodium hydroxide solution was added, the temperature was raised to 80℃, and the reaction was carried out for 2h. The iron salt reacted in situ to generate magnetic particles that were deposited on the surface of the AIE polymer microspheres; the microspheres were centrifuged at 5000rpm and resuspended in water. The process was repeated three times to obtain dual-wavelength aggregation-induced luminescence magnetically encoded microspheres. 3 mL of ammonia water (28%), 1.5 mL of TEOS and 0.6 mL of 3-vinyltrimethoxysilane were added to the above-mentioned aggregation-induced emission magnetically encoded microspheres (0.1 g). After reacting for 6 hours and magnetic separation, 0.5 g of acrylic acid monomer was added, the temperature was raised to 80°C, and after reacting for 8 hours and magnetic separation, carboxyl-modified AIE magnetically encoded microspheres were obtained.

[0137] The dosage of AIE-R1 molecules was changed to 0.001 mg, 0.01 mg, 0.025 mg, 0.05 mg, 0.1 mg, and 0.5 mg respectively to obtain carboxyl-modified AIE magnetic encoded microspheres with different coding intensities (other parameters remained unchanged).

[0138] 2. Antibody-1 labeled AIE magnetically encoded microspheres

[0139] The prepared carboxyl modified AIE magnetic encoded microspheres (AIE-R1 molecule dosage is 5 mg) are added to 10 g MES buffer (pH = 6.5), and after ultrasonic dispersion, 0.0095 g 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is added, and the carboxyl groups are activated in a mixer at a speed of 300 rpm for 5 min. The supernatant is removed by magnetic suction to obtain the activated AIE magnetic encoded microspheres, 3 g boric acid buffer (pH = 8) and 10 μg mouse antibody-1 of cytokine IL-2 are added, and the mixture is placed in a mixer for incubation for 30 min, the supernatant is removed by magnetic suction, 0.5 mL of blocking solution BSA (0.5%) and Tris (0.1%) microsphere preservation solution are added, and ultrasonic dispersion is performed to obtain the IL-2 antibody-1 labeled AIE magnetic encoded microsphere solution (0.2 g / mL).

[0140] The preparation method of the AIE magnetic encoded microsphere solution labeled with antibody-1 corresponding to the cytokines IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ is the same as above, except that the mouse antibody-1 and carboxyl-modified AIE magnetic encoded microspheres of the cytokine IL-2 are replaced by the mouse antibody-1 and carboxyl-modified AIE magnetic encoded microspheres of the cytokine IL-4 (the amount of AIE-R1 molecules is 0.001 mg), the mouse antibody-1 and carboxyl-modified AIE magnetic encoded microspheres of the cytokine IL-6 (the amount of AIE-R1 molecules is 0.01 mg), respectively. ), mouse antibody-1 of cytokine IL-10 and carboxyl-modified AIE magnetic encoded microspheres (AIE-R1 molecule dosage is 0.025 mg), mouse antibody-1 of cytokine IL-17 and carboxyl-modified AIE magnetic encoded microspheres (AIE-R1 molecule dosage is 0.05 mg), mouse antibody-1 of cytokine TNF-α and carboxyl-modified AIE magnetic encoded microspheres (AIE-R1 molecule dosage is 0.1 mg), mouse antibody-1 of cytokine IFN-γ and carboxyl-modified AIE magnetic encoded microspheres (AIE-R1 molecule dosage is 0.5 mg).

[0141] 3. Antibody-2 labeled AIE nanofluorescent microspheres

[0142] 1 mg of the detected AIE-N1 molecule was weighed, dissolved in 1 mL of tetrahydrofuran, added to an aqueous solution of carboxyl-modified blank polymer nanospheres (particle size 500 nm) (the mass of the carboxyl-modified blank polymer nanospheres was 0.1 g, and the mass of water was 10 g), and ultrasonically treated at a power of 100 W for 1 min. After the swelling reaction was closed for 2 h, the solvent was evaporated open for 4 h, and the supernatant was removed by centrifugation to obtain carboxyl-modified AIE nano fluorescent microspheres.

[0143] The obtained carboxyl-modified AIE nano fluorescent microspheres were activated, coupled with IL-2 antibody-2, and blocked according to the method of the above step (ii) to obtain an IL-2 antibody-2 labeled AIE nano fluorescent microsphere solution (0.1 μg / mL) (wherein IL-2 antibody-2 is a mouse antibody-2 of cytokine IL-2).

[0144] The preparation method of the AIE nano fluorescent microsphere solution labeled with antibody-2 corresponding to the cytokines IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ is the same as above, the only difference is that the mouse antibody-2 of the cytokine IL-2 is replaced by the mouse antibody-2 of the cytokine IL-4, IL-6, IL-10, IL-17, TNF-α or IFN-γ.

[0145] 4. Determination of multiple marker immunoassays

[0146] 10 μL of each of the seven different types of antibody-1 labeled AIE magnetic encoded microsphere solutions and 10 μL of each of the corresponding antibody-2 labeled AIE nano fluorescent microsphere solutions were added to the same flow tube, and then 5 μL of the sample to be tested (a mixed solution of seven cytokines IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ) was added. After magnetic separation, the coding peak was obtained through the coding channel of the flow cytometer, and the types of cytokines in the solution to be tested were distinguished by the coding channel and intensity; the fluorescence intensity of the AIE nano fluorescent microspheres was detected to achieve the quantitative determination of each cytokine in the sample to be tested ( Figure 4 ).

[0147] The morphology of AIE magnetically encoded microspheres was observed using a field emission SEM electron microscope. The microspheres showed a regular spherical structure with a statistical particle size of about 5 μm (e.g. Figure 1 ). The particle size of the antibody-2 labeled AIE nano fluorescent microspheres was tested using a DLS nanoparticle size analyzer, and the Z-average particle size was 500nm. The fluorescence spectrum of the antibody-2 labeled AIE nano fluorescent microspheres was tested using a fluorescence spectrometer, and the excitation wavelength of AIE was 400nm and the emission wavelength was 550nm. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer, and the minimum detection limit was as shown in Table 1 below. The multiple marker analysis detection effect was good.

[0148] Example 2

[0149] The 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 50 nm carboxyl-modified blank polymer nanospheres. Others were the same as in Example 1. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer. The minimum detection limit is shown in Table 1 below. The multiple marker analysis detection effect was good.

[0150] Example 3

[0151] The 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 40 nm carboxyl-modified blank polymer nanospheres. Others were the same as in Example 1. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer. The minimum detection limit is shown in Table 1 below. The multiple marker analysis detection effect was good.

[0152] Example 4

[0153] The 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 30 nm carboxyl-modified blank polymer nanospheres. Others were the same as in Example 1. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer. The minimum detection limit is shown in Table 1 below. The multiple marker analysis detection effect was good.

[0154] Example 5

[0155] The 5 μm blank polymer microspheres in step (i) of Example 1 were replaced with 6 μm blank polymer microspheres, and the 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 30 nm carboxyl-modified blank polymer nanospheres. All other aspects were the same as in Example 1. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer, and the minimum detection limit was shown in Table 1 below, and the multiple marker analysis detection effect was good.

[0156] Example 6

[0157] The 5 μm blank polymer microspheres in step (i) of Example 1 were replaced with 8 μm blank polymer microspheres, and the 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 30 nm carboxyl-modified blank polymer nanospheres. All other aspects were the same as in Example 1. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer, and the minimum detection limit was shown in Table 1 below, and the multiple marker analysis detection effect was good.

[0158] Example 7

[0159] The 5 μm blank polymer microspheres in step (i) of Example 1 were replaced with 10 μm blank polymer microspheres, and the 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 30 nm carboxyl-modified blank polymer nanospheres. All other aspects were the same as in Example 1. The minimum detection concentration of the seven cytokine markers was tested using an analytical flow cytometer, and the minimum detection limit was shown in Table 1 below, and the multiple marker analysis detection effect was good.

[0160] Table 1 Effects of AIE-encoded particle size, detection microsphere particle size and emission wavelength on seven-fold cytokine marker immunoassay

[0161]

[0162]

[0163] Comparative Example 1

[0164] The 5 μm blank polymer microspheres in step (i) of Example 1 were replaced with 1 μm blank polymer microspheres, and the 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 50 nm carboxyl-modified blank polymer nanospheres. Others were the same as in Example 1.

[0165] The morphology of AIE magnetically encoded microspheres was observed using a field emission SEM electron microscope. The microspheres showed a regular spherical structure with a statistical particle size of about 1 μm. The particle size of antibody-2 labeled AIE nanofluorescent microspheres was tested using a DLS nanoparticle size analyzer, and the Z-average particle size was 50 nm. The fluorescence spectrum of antibody-2 labeled AIE nanofluorescent microspheres was tested using a fluorescence spectrometer. The excitation wavelength of AIE was 400 nm and the emission wavelength was 550 nm. The analytical flow cytometer was used for testing. Due to the small particle size of the encoded microspheres and the large noise points, the encoding failed and the detection effect was poor.

[0166] Comparative Example 2

[0167] The 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 1000 nm carboxyl-modified blank polymer nanospheres. Others were the same as in Example 1.

[0168] The morphology of AIE magnetically encoded microspheres was observed using a field emission SEM electron microscope. The microspheres showed a regular spherical structure with a statistical particle size of about 5μm. The particle size of antibody-2 labeled AIE nanofluorescent microspheres was tested using a DLS nanoparticle sizer, and the Z-average particle size was 1000nm. The fluorescence spectrum of antibody-2 labeled AIE nanofluorescent microspheres was tested using a fluorescence spectrometer. The excitation wavelength of AIE was 400nm and the emission wavelength was 550nm. The analytical flow cytometer was used for testing. Due to the large particle size of the AIE nanofluorescent microspheres and the weak ability to bind antibodies, the detection sensitivity was poor and the detection effect was poor.

[0169] Comparative Example 3

[0170] The 500 nm carboxyl-modified blank polymer nanospheres in step (iii) of Example 1 were replaced with 50 nm carboxyl-modified blank polymer nanospheres, and the AIE-N1 molecules in step (iii) of Example 1 were replaced with AIE-R1 molecules. Others were the same as in Example 1.

[0171] The morphology of AIE magnetically encoded microspheres was observed using a field emission SEM electron microscope. The microspheres showed a regular spherical structure with a statistical particle size of about 5μm. The particle size of the antibody-2 labeled AIE nanofluorescent microspheres was tested using a DLS nanoparticle sizer, and the Z-average particle size was 50nm. The fluorescence spectrum of the antibody-2 labeled AIE nanofluorescent microspheres was tested using a fluorescence spectrometer. The excitation wavelength of AIE was 400nm and the emission wavelength was 620nm. Using an analytical flow cytometer for testing, since the emission wavelength of the AIE nanofluorescent microspheres was around 620nm, which overlapped with the AIE emission spectrum of the encoded microspheres, the quantitative detection of the cytokine concentration failed and the detection effect was poor.

[0172] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement modes and shall be included in the protection scope of the present invention.

Claims

1. An immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres, characterized in that: It includes AIE magnetically encoded microspheres labeled with antibody-1 and AIE nano-microspheres labeled with antibody-2; The particle size range of the AIE magnetically encoded microspheres is 1.5 μm-20 μm; the particle size range of the AIE nanospheres is 10 nm-1000 nm; The AIE nanospheres include carboxyl-modified blank polymer nanospheres and AIE-N molecules; the AIE-N molecules are embedded inside the carboxyl-modified blank polymer nanospheres; The AIE magnetically encoded microspheres are dual-wavelength aggregation-induced luminescence magnetically encoded microspheres, including AIE polymer microspheres and magnetic particles; the AIE polymer microspheres are obtained by embedding AIE molecules inside blank polymer microspheres, and the magnetic particles are deposited on the surface of the AIE polymer microspheres; the AIE molecules include AIE-R molecules and AIE-IR molecules; The difference between the maximum emission wavelength of the AIE-IR molecule and the maximum emission wavelength of the AIE-R molecule is in the range of 160 nm to 290 nm, and satisfies Δλ≥185. Where I / I0 is the average value of the fluorescence intensity ratio of AIE-IR molecules and AIE-IR molecules before and after embedding, λ IR is the maximum emission wavelength of the AIE-IR molecule, λ R is the maximum emission wavelength of the AIE-R molecule.

2. The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to claim 1, characterized in that: The mass amount of the AIE nanoparticles labeled with antibody-2 is 0.001-0.01wt% of the mass amount of the AIE magnetic encoding microparticles labeled with antibody-1; The encoding capacity of the AIE magnetically encoded microspheres is ≥ 4, and the CV value of the flow fluorescence signal and the CV value of the flow FCS are both less than 10%; The emission wavelength range of the AIE nanospheres is 450nm-550nm; The antibody-1 and antibody-2 can specifically bind to the same antigen.

3. The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to claim 2, characterized in that: The antibody-1 is selected from at least one of IL-2 monoclonal antibody, IL-4 monoclonal antibody, IL-6 monoclonal antibody, IL-10 monoclonal antibody, IL-17 monoclonal antibody, TNF-α monoclonal antibody and IFN-γ monoclonal antibody; antibody-2 is selected from the anti-antibody of antibody-1; The antibody-1 and antibody-2 are mouse antibodies.

4. The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to claim 2, characterized in that: The encoding capacity of the AIE magnetically encoded microspheres is ≥24.

5. The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to claim 1, characterized in that: In the AIE nanospheres, The carboxyl-modified blank polymer nanospheres are selected from at least one of carboxyl-modified polystyrene microspheres, carboxyl-modified polymethyl methacrylate microspheres and carboxyl-modified polyglycidyl acrylate microspheres; The AIE-N molecules are embedded in the blank polymer nanospheres modified with carboxyl groups by an active swelling method, wherein the amount of the AIE-N molecules used in the active swelling method is 0.01-10 wt % of the amount of the blank polymer nanospheres modified with carboxyl groups. The AIE-N molecules in the AIE nanospheres are selected from at least one of the following AIE-N1 to AIE-N10: In the dual-wavelength aggregation-induced luminescence magnetically encoded microspheres, The blank polymer microspheres are selected from at least one of polystyrene microspheres, polymethyl methacrylate microspheres and polyglycidyl acrylate microspheres; The magnetic particles are Fe3O4; The AIE-R molecule is selected from at least one of the following AIE-R1 to AIE-R16 molecules: The AIE-IR molecule is selected from at least one of the following AIE-IR1 to AIE-IR10 molecules: The AIE molecules are embedded in the blank polymer microspheres by an active swelling method, wherein the amount of the AIE molecules used in the active swelling method is 0.01-10wt% of the amount of the blank polymer microspheres, wherein the mass amount of the AIE-R molecules accounts for 0.01% to 1000% of the mass amount of the AIE-IR molecules; The magnetic particles are deposited on the surface of the AIE polymer microspheres by an in-situ precipitation method of iron salts, wherein the amount of iron salts used in the in-situ precipitation method is 0.1-25 wt % of the amount of blank polymer microspheres used.

6. The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to claim 5, characterized in that: In the AIE nanospheres, The active swelling method is to allow AIE-N molecules to swell with carboxyl-modified blank polymer microspheres in a swelling agent so that the AIE-N molecules are embedded in the carboxyl-modified blank polymer microspheres. In the active swelling method, the swelling agent is selected from at least one of dichloromethane, tetrahydrofuran, chloroform, anisole, benzyl alcohol and toluene, and the particle size of the blank polymer microspheres modified with carboxyl groups ranges from 10 nm to 500 nm; In the dual-wavelength aggregation-induced luminescence magnetically encoded microspheres, The active swelling method is to allow the AIE molecules to swell with the blank polymer microspheres in a swelling agent so that the AIE molecules are embedded in the blank polymer microspheres. In the active swelling method, the swelling agent is selected from at least one of dichloromethane, tetrahydrofuran, chloroform, anisole, benzyl alcohol and toluene, and the particle size of the blank polymer microspheres ranges from 1.5 μm to 20 μm; The in-situ precipitation method is to add an alkaline solution to react with the iron salt chelated on the surface of the AIE polymer microspheres in situ to generate magnetic particles that are deposited on the surface of the AIE polymer microspheres; In the in-situ precipitation method, the surface of the AIE polymer microspheres is modified by sulfonation, the alkaline solution is selected from at least one of sodium hydroxide solution, ammonia water, potassium hydroxide solution and sodium bicarbonate solution; the iron salt is selected from at least one of trivalent iron salt and divalent iron salt; the trivalent iron salt is selected from at least one of ferric chloride hexahydrate and anhydrous ferric chloride; the divalent iron salt is selected from at least one of ferrous chloride tetrahydrate, ferrous chloride dihydrate, ferrous sulfate and ferrous sulfate heptahydrate.

7. The method for preparing an immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to any one of claims 1 to 6, characterized in that: The following steps are involved: (1) Carboxyl modification, carboxyl activation, and antibody-1 coupling of the AIE magnetically encoded microspheres to obtain antibody-1 labeled AIE magnetically encoded microspheres; (2) activating the carboxyl group of the AIE nanospheres and coupling with antibody-2 to obtain antibody-2 labeled AIE nanospheres; The immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres is obtained.

8. The preparation method according to claim 7, characterized in that: In step (1), the carboxyl modification comprises: mixing and reacting the AIE magnetic encoded microspheres, a base, TEOS and a silane coupling agent, magnetically separating, and adding a monomer containing a double bond and a carboxyl group to react to obtain the carboxyl modified AIE magnetic encoded microspheres; In step (1), the activation of carboxyl groups comprises: dispersing carboxyl-modified AIE magnetic encoded microspheres in an acidic buffer, adding a carbodiimide condensation reagent, and stirring to activate the carboxyl groups, thereby obtaining carboxyl-activated AIE magnetic encoded microspheres; In step (1), the antibody-1 coupling comprises: dispersing the AIE magnetically encoded microspheres with activated carboxyl groups in an alkaline buffer, adding the antibody-1, incubating with stirring, separating by magnetic absorption, adding a blocking solution and a preservation solution, and obtaining the AIE magnetically encoded microspheres labeled with the antibody-1; In step (2), the activation of carboxyl groups comprises: dispersing the carboxyl-modified AIE nanoparticles in an acidic buffer, adding a carbodiimide condensation reagent, and stirring the reaction to activate the carboxyl groups, thereby obtaining AIE nanoparticles with activated carboxyl groups; In step (2), the antibody-2 coupling includes: dispersing the AIE nanoparticles with activated carboxyl groups in an alkaline buffer, adding antibody-2, incubating with stirring, separating by magnetic attraction, adding blocking solution and preservation solution, and obtaining AIE nanoparticles labeled with antibody-2.

9. Use of the immunoassay reagent based on AIE magnetically encoded microspheres and AIE nanospheres according to any one of claims 1 to 6 in antigen immunoassay for non-diagnostic purposes, characterized in that: The following steps are involved: The AIE magnetically encoded microspheres labeled with antibody-1 and the AIE nanospheres labeled with antibody-2 were added to the test solution containing the corresponding antigens, and after the reaction, they were separated by magnetic absorption, and the encoding peaks and fluorescence quantitative detection concentrations were obtained by flow cytometry.

10. The use according to claim 9, characterized in that: The mass amount of the corresponding antigen is 0.01-1wt% of the mass amount of the AIE nanoparticles labeled with antibody-2; The antibody-1 labeled AIE magnetic coded microspheres include AIE magnetic coded microspheres with different coding intensities respectively labeled with antibodies-1 of multiple different antigens, and the antibody-2 labeled AIE nanospheres include AIE nanospheres labeled with antibodies-2 corresponding to multiple different antigens.